Clinical Trial Update: SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating SYS6002 versus standard chemotherapy in locally advanced or metastatic urothelial carcinoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• SYS6002

Snippet

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Conditions: Urothelial Carcinoma | Phase 3 | Status: NOT_YET_RECRUITING